GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for MVP

MVP

Official Title

Mechanical Valve Registry (MVP)

Status

Completed

Overview

To determine if postoperative bridging therapy with full-dose heparin anticoagulation is superior to low-dose heparin bridging therapy in the immediate post-mechanical heart valve implantation period; and whether postoperative bridging therapy with LMWH is superior to UFH bridging therapy in the immediate post-mechanical heart valve implantation period.

Study Design

Retropsective chart review of use of antithrombotic use over 30 days after valve surgery.

Primary Endpoint

Primary: Determine whether postoperative bridging therapy with full-dose heparin anticoagulation is superior to low-dose heparin bridging therapy in the immediate post-mechanical heart valve implantation period.

Secondary: Determine whether postoperative bridging therapy with LMWH is superior to UFH bridging therapy in the immediate post-mechanical heart valve implantation period.

Number of Patients

1777

Number of Sites

5

Number of Countries

1

Study Period

2010–2013

Principal Investigator

Richard Whitlock

Program Manager

Susan Chrolavicius

Research Coordinator

Jessica Vincent